公开(公告)号：US20190144554A1

公开(公告)日：2019-05-16

申请号：US15780268

申请日：2016-12-01

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/62 ,  C07K16/30 ,  A61P35/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20210324096A1

公开(公告)日：2021-10-21

申请号：US17108373

申请日：2020-12-01

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20190315877A1

公开(公告)日：2019-10-17

申请号：US16451714

申请日：2019-06-25

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C12N15/62 ,  C07K16/46 ,  C07K16/30 ,  A61P35/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20230293680A1

公开(公告)日：2023-09-21

申请号：US18017241

申请日：2021-07-23

Applicant: Genmab B.V.

Inventor： Hilma VAN DER HORST ,  Tuna MUTIS ,  Kristin STRUMANE ,  Esther BREIJ ,  Marije OVERDIJK

IPC: A61K39/395 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00 ,  A61K2039/507

Abstract: The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.